David Epstein

Chairman of the Board

David is an industry veteran and most recently served as Seagen’s Chief Executive Officer and as a member of its Board of Directors. Under his leadership, Seagen significantly grew its portfolio of innovative cancer medicines and was acquired for more than $43 billion by Pfizer in December 2023. Prior to Seagen, he served as Novartis Pharmaceuticals’ Chief Executive Officer. David has more than 30 years of drug development, deal-making, commercialization and leadership experience on a global scale. Over the course of his career, he has led the  development and commercialization of over 30 new molecular entities, including Glivec, Tasigna, Gilenya, Cosentyx, Entresto and Padcev. He was named by FierceBiotech as one of the “25 most influential people in biopharma”.

By continuing to use the site, you agree to the use of cookies. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.